Pattern of Microbial Infection in AECOPD Patients and Its Sensitivity to Antibiotics

NCT06123780 | Unknown

• 1 other identifier: Bacteriology in AECOPD
• Study Type: observational
• Target: 140
• Locations: 0 countries
• Sites: N/A

Brief Summary

Measurement of bacterial species causing AECOPD and their Sensitivity pattern to antibiotics.

Conditions

Acute Exacerbation COPD

Outcome Measures

Primary Outcomes (2)

• Pattern of Microbial infection based on sputum culture results.

  Identification of causative Microbial organisms of AECOPD based on results of sputum culture.

  Baseline

• Pattern of antimicrobial sensitivities based on sputum culture results.

  Identification of antimicrobial sensitivities and resistance patterns in this population based on results of sputum culture.

  Baseline

Secondary Outcomes (1)

• Hospital length of stay

  Baseline

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Demographic characteristics of these patients will be recorded, including sex, age, smoking status, underlying comorbidities, occupation and number of exacerbations. Clinical features will be recorded including increase grade of dyspnea , purulence and amount of sputum , history of previous NIV or MV. Spirometry as a confirmation tool of COPD. Arterial blood gases on admission. Complete blood count ( CBC ) and ESR Radiological profile of COPD patients. Sputum sample ; Spontaneous sputum sample by asking the patient to cough up sputum into sterile container. NIV patients : by spontaneous sputum sample. MV patients : by sputum suction through the endotracheal tube .

You may qualify if:

• Must be at least 18 years of age and less than 80 years of age for both genders
• Confirmed diagnosis of COPD by spirometry
• Must be an AECOPD patient (with increased grade of dyspnea, increased purulence and amount of sputum) and admitted to the chest department or ICU
• Positive sputum culture

You may not qualify if:

• Age less than 18 years old
• Any associated pulmonary co-morbidity

Sponsors & Collaborators

• Assiut University: lead

Related Publications (5)

• Venkatesan P. GOLD report: 2022 update. Lancet Respir Med. 2022 Feb;10(2):e20. doi: 10.1016/S2213-2600(21)00561-0. Epub 2021 Dec 20. No abstract available.

  PMID: 34942084 BACKGROUND

• Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000 May;117(5 Suppl 2):398S-401S. doi: 10.1378/chest.117.5_suppl_2.398s.

  PMID: 10843984 BACKGROUND

• Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008 Nov 27;359(22):2355-65. doi: 10.1056/NEJMra0800353. No abstract available.

  PMID: 19038881 BACKGROUND

• Momanyi L, Opanga S, Nyamu D, Oluka M, Kurdi A, Godman B. Antibiotic Prescribing Patterns at a Leading Referral Hospital in Kenya: A Point Prevalence Survey. J Res Pharm Pract. 2019 Oct 16;8(3):149-154. doi: 10.4103/jrpp.JRPP_18_68. eCollection 2019 Jul-Sep.

  PMID: 31728346 BACKGROUND

• Slone DE, Ganjam VK, Purohit RC, Ravis WR. Cortisol (hydrocortisone) disappearance rate and pathophysiologic changes after bilateral adrenalectomy in equids. Am J Vet Res. 1983 Feb;44(2):276-9.

  PMID: 6830017 BACKGROUND

Study Officials

• Khaled H. Ahmed, Professor

  Assuit U

  STUDY DIRECTOR

• Samiaa H Sadek, Professor

  Assuit U

  STUDY DIRECTOR

Central Study Contacts

Mariam Nazif Abdel-Tawab, MD

CONTACT

1228168408; marmar.mera69@yahoo.com

Ahmed H Mohammed, Professor

CONTACT

01006160783

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant lecturer

Study Record Dates

• First Submitted: October 11, 2023
• First Posted: November 9, 2023
• Study Start: December 1, 2023
• Primary Completion: November 1, 2024
• Study Completion: December 1, 2024
• Last Updated: November 22, 2023

Record last verified: 2023-11